Oncotarget

Research Papers:

Identifying the druggable interactome of EWS-FLI1 reveals MCL-1 dependent differential sensitivities of Ewing sarcoma cells to apoptosis inducers

Kalliopi Tsafou, Anna Maria Katschnig, Branka Radic-Sarikas, Cornelia Noëlle Mutz, Kristiina Iljin, Raphaela Schwentner, Maximilian O. Kauer, Karin Mühlbacher, Dave N.T. Aryee, David Westergaard, Saija Haapa-Paananen, Vidal Fey, Giulio Superti-Furga, Jeffrey Toretsky, Søren Brunak and Heinrich Kovar _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Press Release  |  Order a Reprint

Oncotarget. 2018; 9:31018-31031. https://doi.org/10.18632/oncotarget.25760

Metrics: PDF 767 views  |   HTML 1719 views  |   ?  


Abstract

Kalliopi Tsafou1,7,*, Anna Maria Katschnig3,*, Branka Radic-Sarikas2,3,*, Cornelia Noëlle Mutz3, Kristiina Iljin5, Raphaela Schwentner3, Maximilian O. Kauer3, Karin Mühlbacher3, Dave N.T. Aryee3,4, David Westergaard1, Saija Haapa-Paananen5, Vidal Fey5, Giulio Superti-Furga2, Jeffrey Toretsky6, Søren Brunak1 and Heinrich Kovar3,4

1Disease Systems Biology, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

2CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria

3Children’s Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria

4Department of Pediatrics, Medical University of Vienna, Vienna, Austria

5Medical Biotechnology, VTT Technical Research Centre of Finland, Espoo, Finland

6Department of Oncology, Georgetown University, Medical Center, Washington, DC, USA

7Current address: Broad Institute of MIT and Harvard, Cambridge, MA, USA

*These authors contributed equally to this work

Correspondence to:

Heinrich Kovar, email: heinrich.kovar@ccri.at

Keywords: high-throughput compound screening; Ewing sarcoma; drug-target network; apoptosis; BCL-2 inhibitors

Received: March 07, 2018     Accepted: June 22, 2018     Published: July 24, 2018

ABSTRACT

Ewing sarcoma (EwS) is an aggressive pediatric bone cancer in need of more effective therapies than currently available. Most research into novel targeted therapeutic approaches is focused on the fusion oncogene EWSR1-FLI1, which is the genetic hallmark of this disease. In this study, a broad range of 3,325 experimental compounds, among them FDA approved drugs and natural products, were screened for their effect on EwS cell viability depending on EWS-FLI1 expression. In a network-based approach we integrated the results from drug perturbation screens and RNA sequencing, comparing EWS-FLI1-high (normal expression) with EWS-FLI1-low (knockdown) conditions, revealing novel interactions between compounds and EWS-FLI1 associated biological processes. The top candidate list of druggable EWS-FLI1 targets included genes involved in translation, histone modification, microtubule structure, topoisomerase activity as well as apoptosis regulation. We confirmed our in silico results using viability and apoptosis assays, underlining the applicability of our integrative and systemic approach. We identified differential sensitivities of Ewing sarcoma cells to BCL-2 family inhibitors dependent on the EWS-FLI1 regulome including altered MCL-1 expression and subcellular localization. This study facilitates the selection of effective targeted approaches for future combinatorial therapies of patients suffering from Ewing sarcoma.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25760